规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | DSR-6434 is a highly potent TLR7 agonist with EC50 value of 7.2nM for activation of hTLR7 in NF-κB SEAP reporter assay. Administration of DSR-6434, i.v., inhibited lung metastasis by 78% at dose of 0.1mg/kg and suppressed lung metastasis completely at dose of 1 mg/kg on HM-1 metastasis model. DSR-6434 at concentration<5μM alone does not affect tumor cell( CT26 or KHT) clonogenic potential or radio sensitivity in vitro. Intravenous administration of 0.1mg/kg DSR-6434 in combination with IR improved survival in syngeneic models of colorectal carcinoma and fibrosarcoma in vivo, which may due to priming an antitumor CD8+ T-cell response. |
作用机制 | DSR-6434 possesses 8-oxoadenine structure which is a novel structural class IFN inducer.[1] |
Dose | Mice: 0.01 mg/kg, 0.1 mg/kg[2] (i.v.) |
Administration | i.v. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.50mL 0.50mL 0.25mL |
12.49mL 2.50mL 1.25mL |
24.97mL 4.99mL 2.50mL |
CAS号 | 1059070-10-8 |
分子式 | C19H28N8O2 |
分子量 | 400.478 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,2-8°C |
溶解度 |
DMSO: 120 mg/mL(299.64 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |